Compare Novartis AG (NVS) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs PepsiCo, Inc. — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while PepsiCo, Inc. trades at $138.2 (market cap $187.99B). The key difference: Novartis AG is the larger of the two by market cap, and PepsiCo, Inc. pays the higher dividend (4.3%). Which is the better fit depends on your goals.
| NVS | PEP | |
|---|---|---|
Market Cap | $298.18B | $187.99B |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $170.44 |
52-Week Low | $119.31 | $134.95 |
Enterprise Value | $339.50B | $230.48B |
Dividend Yield | 3.02% | 4.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 10.78% net margin and 51.59% ROE, though Q3 2026 earnings are pending. Recent news highlights price adjustments on snack products and sponsorship changes, while analysts maintain a consensus Buy rating with $158.79 price target.
PEP offers steady dividend income and operational stability, but faces near-term pressure from consumer resistance to price hikes and competitive threats. The stock trades below consensus target with mixed technical indicators, presenting potential value for long-term investors willing to navigate current volatility and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
